Article citationsMore>>

Takimoto, C.H., Hammond-Thelin, L.A., Latz, J.E., Forero, L., Beeram, M., Forouzesh, B., de Bono, J., Tolcher, A.W., Patnaik, A., Monroe, P., Wood, L., Schneck, K.B., Clark, R. and Rowinsky, E.K. (2007) Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer. Clinical Cancer Research, 13, 2675-2683.
https://doi.org/10.1158/1078-0432.CCR-06-2393

has been cited by the following article:

• TITLE: Predictive Factors of Severe Toxicities of Pemetrexed-Containing Chemotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer

  AUTHORS: Yuki Katsuya, Yuichiro Takeda, Go Naka, Haruhito Sugiyama

  KEYWORDS: Non-Squamous Non-Small Cell Lung Cancer, Pemetrexed, Toxicity, Clinical Settings

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.11, November 28, 2017

  ABSTRACT: Background: Pemetrexed (PEM) is an efficacious multi-targeted antifolate with acceptable toxicities for non-squamous non-small cell lung cancer (non-Sq NSCLC). However, in the clinical setting, PEM has more severe adverse effects than those reported. The aim of this study was to identify the factors for the toxicities of PEM-containing chemotherapy in non-Sq NSCLC patients in the clinical setting. Patients and Methods: We retrospectively evaluated the factors related to PEM toxicities in chemotherapy-naive patients with non-Sq NSCLC from September 2009 to July 2013 at our hospital. Logistic regression model was used in the univariate and multivariate analyses. Results: In total, 104 patients were analyzed. Grades 3 to 5 hematologic toxicities were frequent and included neutropenia (42%), febrile neutropenia (7%), anemia (18%), thrombocytopenia (17%), and disseminated intravascular coagulation (2%). On multivariate analyses, the predictors were poor performance status (PS) [odds ratio (OR): 4.89, 95% confidence interval (CI): 1.22 - 19.4] and low body mass index (OR: 1.44, 95% CI: 1.05 - 1.98) for febrile neutropenia; concomitant chronic infectious disease (OR: 6.63, 95% CI: 1.59 - 27.5) and bevacizumab use (OR: 3.57, 95% CI: 1.36 - 9.32) for neutropenia; poor PS (OR: 3.02, 95% CI: 1.33 - 6.85) for thrombocytopenia; and low serum albumin level (OR: 0.22, 95% CI: 0.08 - 0.63) for non-hematologic toxicities. Conclusions: In addition to the previously reported predictors of PEM toxicities, the presence of concomitant chronic infectious disease was associated with hematologic toxicities. Patient groups who are not sufficiently evaluated in clinical trials should be carefully monitored for the development of more toxicities than expected.